Funding Opportunities

The Pharmacotherapies for Alcohol and Substance Abuse (PASA) Consortium is funded by the Congressionally Directed Medical Research Programs (CDMRP) as part of its Alcohol and Substance Abuse Research Program (ASARP).  The goal of the PASA Consortium is to fund study applications for developing new medications that can be brought to therapeutic use to improve treatment outcomes for alcohol and substance use disorders (ASUD), especially as related to post-traumatic stress disorder (PTSD) and traumatic brain injury (TBI).

This current Clinical Trial Research Funding Opportunity is focused on developing new medications that 1) already have an IND for human studies and 2)that can improve treatment outcomes for ASUD related to PTSD and TBI. The PASA Consortium is administered by a Management Core led by RTI International in collaboration with the Baylor College of Medicine and the Uniformed Services University.

For more information on this opportunity, including application process and timelines, please use the link below: https://pasa.rti.org/About/Grant-Program
This Notice is part of the NIH Helping to End Addiction Long-Term (HEAL) Initiative, an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis.

NCATS and other participating institutes and Centers (ICs) are inviting investigators with relevant active research project grants and cooperative agreements to submit administrative supplements, according to PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional), for funded projects to identify and validate new pain and opioid use disorder (OUD) targets from within the understudied Druggable Genome.

For more information on this opportunity, including application process and timelines, please use the link below: https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-008.html?utm_source=daRSS&utm_medium=email&utm_campaign=da-FOA
Offers research grants to non-profit ((501)(c)(3)) organizations, for research into the causes of alcoholism or substance abuse. Basic, clinical and social science proposals will be considered. The Trust expects to grant approximately $225,000 this year and will consider proposals that request up to $75,000. Please send brief summary proposal (2-3 pages), proposed budget, copy of institution’s (501)(c)(3) letter, and investigator’s bio-sketch. Grant moneys may not be used for tuition and no more than 10% of amount granted may be used for indirect costs. Please include an address for the Trust's response, which will be sent via U.S. mail. Please send application materials to Katharine G. Lidz, 31 Independence Place, Chesterbrook, PA 19087. Applications must be postmarked or placed with courier service on or before Friday, September 8, 2023. Applications sent via email will not be accepted. Additional information may be requested after initial review. Before any grant may be renewed, the grant recipient must submit a progress report to the Trust. If you have any questions, please contact the Trust by telephone (610) 647-4974 or e-mail at mcmanustrust@gmail.com.
Applications now open for Health Equity Scholars for Action Are you an early-career researcher ready to bring your perspective and background to create a clearer path to health and wellbeing? Or do you know someone who is? Health Equity Scholars for Action (HES4A) supports the career development and academic advancement of historically underrepresented researchers conducting health equity research. HES4A scholars receive: • Funding for research on potential solutions to improve health, equity, and well-being for all; • Coaching and mentorship to help develop and strengthen technical skills and explore career opportunities; and, • A professional network of community partners, researchers, public health practitioners, and funders committed to advancing the health equity research field. Research is stronger, more accurate, actionable, and equitable when people with varied perspectives and lived experiences are designing and conducting it. Is your research eligible? Learn more about eligibility, application requirements, and applicant webinar. Apply by May 31, 2023  
American Psychiatric Association Foundation invites applications for mental health and substance use disorder projects The American Psychiatric Association Foundation invites applications for its Helping Hands Grants Program. Established in 2005, the program aims to encourage medical students to participate in community service activities, raise awareness of mental illness and the importance of early recognition of illness, and build interest among medical students in the psychiatric field and working in underserved communities. To that end, grants of up to $5,000 will be awarded to medical schools supporting mental health and substance use disorder projects, particularly in underserved minority communities. Medical students should create and manage projects that may be conducted in partnership with community agencies or conjunction with ongoing medical school outreach activities. To be eligible, projects must be supervised by at least one psychiatrist. For complete program guidelines, application instructions, and information about previous grantees, see the American Psychiatric Association Foundation website.
The Pharmacotherapies for Alcohol and Substance Use Disorder Alliance (PASA) is funded by the Congressionally Directed Medical Research Programs (CDMRP) as part of its Alcohol and Substance Use Disorder Research Program (ASUDRP). The goal of the PASA is to fund research for developing new medications that can improve treatment outcomes for alcohol and substance use disorders (ASUD), especially as related to post-traumatic stress disorder (PTSD) and other psychological disorders. Research proposed can be for an alcohol use disorder (AUD), substance use disorder (SUD), or both an AUD and SUD. This PASA Request for Application (RFA) #7 cycle includes has three aims: o Aim 1: Discover: Test new chemical entities and repurpose existing medications in strictly pre-clinical and non-clinical models of ASUD with comorbid PTSD and/or other psychological disorders. o Aim 2: Phase 1 First-in-Human Safety: Conduct clinical trials of potential medications that include assessment of medical safety and doses for potential efficacy in subjects with ASUD and comorbid PTSD and/or other psychological disorders. o Aim 3: Phase 2 Efficacy: Conduct multiple site clinical trials to test preliminary efficacy and safety of potential medications or medication combinations in humans with ASUD and comorbid PTSD and/or other psychological disorders, and to also explore precision medicine tools for matching patients to these medications. • RFA 7a/Planning Award: o Small-cost and short-duration planning award concerning a specific compound or combination of compounds; to determine the clinical development plan and associated clinical trial(s) needed to advance the compound (or combination of compounds) to FDA approval for ASUD treatment comorbid with PTSD or other psychological disorders. o For this RFA (7a/Planning Award):  Soliciting for planning awards under Aims 2 and/or Aim 3 human participant clinical trials. o Timeline:  Letter of Intent 06/30/2023  Full Application Deadline 07/14/2023 • RFA 7b/Pre-Clinical: o Full study implementation awards for proof-of-principle pre-clinical animal research to determine which compounds are most appropriate for human research trials. o For this RFA (7b/Pre-Clinical):  Soliciting for research awards under Aim 1 pre-clinical animal research studies. o Timeline:  Letter of Intent 06/30/2023  Full Application Deadline 07/28/2023 • RFA 7c/Non-Clinical: o Full study implementation awards for proof-of-principle non-clinical research to determine which compounds most appropriate for human research trials. additional research. The non-clinical research is intended to increase the potential pool of compounds for investigation in subsequent pre-clinical studies and clinical trials. Approaches to identifying promising compounds for development or repurposing studies that leverage large-scale data through computational-based analysis include, but are not limited to, in silico and augmented intelligence research. o For this RFA (7c/Non-Clinical):  Soliciting for research awards under Aim 1 non-clinical research studies focused on ASUD comorbid with PTSD and other psychological disorders o Timeline:  Letter of Intent 06/30/2023  Full Application Deadline 07/28/2023 • RFA 7d/Expansion Award: o Expansion award to support the continued research of highly impactful studies that were funded by the Pharmacotherapies for Alcohol and Substance Abuse Use Disorder Alliance (PASA) Study Research Planning Program (SRPP). o Timeline:  Letter of Intent 06/30/2023  Full Application Deadline 07/14/2023 The LOIs are largely for planning purposes; no response from PASA is required to proceed with the full application. More information on this opportunity can be found here: https://pasa-research.org/funding-opportunities